Poster Session B

Poster Session B
Friday, October 14
12:30 p.m.-3:30 p.m.

In alphabetical order, not board assignment order

• AGR2: A potential predictive biomarker of tamoxifen resistance in breast cancer, Veronika Brychtova, Masaryk Memorial Cancer Institute, Brno, Czech Republic
• A dendritic-cell targeted lentiviral vaccine vector elicits a strong immune response to the breast cancer antigen, Erbb2, Paul Bryson, University of Southern California, Los Angeles, CA, United States
• A model to study hormone regulation of luminal progenitor cells in estrogen receptor positive breast cancers, Sunshine Axlund, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States
• A role for the adhesion protein junctional adhesion molecule-A (JAM-A) in breast cancer, Elaine McSherry, Ontario Cancer Institute, Toronto, ON, Canada
• Analysis of bisulfite converted breast cancer genomes using microdroplet-based targeted sequencing, Michael Samuels, RainDance Technologies Inc., Lexington, MA, United States
• Analysis of global microRNA expression in breast cancer cells reveals mir-19 and mir-9 to be enriched in triple-negative breast cancer cell lines and regulate BIM expression, Leonard Kusdra, University of California, San Francsico, CA, United States
• Angiotensin 1-7, Angiotensin 1-7-FMOC and Angiotensin II-TOAC peptides inhibit proliferation of T47D and of MDA-MB 231 breast cancer cell lines, Silvana Corrêa-Noronha, Escola Paulista de Medicina da Universidade Federal de São Paulo, São Paulo, Brazil
• Angiotensin1-7 peptide increases apoptosis in tumoral (T47D) epithelial breast cells, Samuel Noronha, Escola Paulista de Medicina da Universidade Federal de São Paulo, São Paulo, Brazil
• Anti-cancer effect of new Metformin Salut compound (Metformin-B) in triple-negative breast cancer cell lines, Kyung-Min Lee, Cancer Research Institute Seoul National University College of Medicine, Seoul, Korea (Rep.)
• Astaxanthin decreases invasion and matrix metalloproteinase activity in breast cancer cells, Kristin Stadelman, Wake Forest School of Medicine, Winston Salem, NC, United States
• β-catenin signal contributes to ErbB2-induced mammary tumor initiation and metastasis, Babette Schade, Goodman Cancer Centre, McGill University, Montreal, QC, Canada
• BRCA1 expression partially correlates with cisplatin response in a panel of primary triple-negative breast cancer xenograft models, Petra ter Brugge, Netherlands Cancer Institute, Amsterdam, The Netherlands
• Breast cancer intrinsic subtype specific interactions with the microenvironment dictate the mechanism of tumor invasion, Tuyen Dang, UT Southwestern Medical Center, Dallas, TX, United States
• CD4+ T cells infiltrating human breast carcinomas nucleate the immune response, Karen Willard-Gallo, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
• Cell signaling network profiling of primary breast cancers from premenopausal women, Catherine Ibarra Drendall, Duke University Medical Center, Durham, NC, United States
• Characterization of a mouse model of breast cancer brain metastasis: Possible role for p75NTR, Wenhong Chen, Wake Forest School of Medicine, Winston-Salem, NC, United States
• Characterization of a voltage-dependent calcium channel subunit in breast cancer metastasis, Nisha Kanwar, The Campbell Family Institute for Breast Cancer Research, Toronto, Canada
• Characterization of the role of TRAF2 in breast cancer, Sandrine Tchatchou, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
• Characterizaton of GPNMB-induced breast cancer invasion, tumor formation and metastasis, Gordana Maric, McGill University, Montreal, Canada
• c-Jun N-Terminal Kinase 1 (JNK1) inhibits tumor growth and metastasis by downregulating epithelial to mesenchymal transition (EMT) and stem-cell related genes, Nancy Ebelt, The University of Texas, Austin, Texas, United States
• C-Met is overexpressed and amplified in a subset of triple negative breast cancers, Agnieszka Witkiewicz, Thomas Jefferson University, Philadelphia, PA, United States
• Constitutively active CXCR4 modulates cadherin switching and epithelial to mesenchymal transition in breast carcinoma cells, Tammy Sobolik-Delmaire, Vanderbilt University Medical Center, Nashville, TN, United States
• Dietary modification of vitamin D3 alters the microenvironment properties of the developing mammary gland, Glendon Zinser, University of Cincinnati, Cincinnati, OH, United States
• Differential expression of SIRT1 and STAT3 during mammary gland involution and mammary tumorigenesis, Sabarish Ramachandran, Georgia Health Sciences University, Augusta, GA, United States
• Differential expressions of EGFR, VEGFA, PLAU, and MAP2K7 in African American and European American primary breast cancer cell lines by PCR array, Khirston Howard, Claflin University, Orangeburg, SC, United States
• Do early life estrogenic exposures pre-program breast tumors to become tamoxifen resistant?, Leena Hilakivi-Clarke, Georgetown University, Washington, DC, United States
• Down-regulation of ANAPC13 and CLTCL1 is an early event during the progression of pre-invasive ductal carcinoma of the breast, Carolina Abuazar, A.C. Camargo Hospital, São Paulo, São Paulo Brazil
• Downregulation of miRNA-29 contributes to progestin-mediated expansion of stem-like cells, Diana Cittelly, University of Colorado at Denver, Aurora, CO, United States
• EBV infection of primary mammary epithelial cells facilitates malignant transformation, Hai Hu, BIDMC / HMS, Boston, MA, United States
• Effects of calcitriol on the expression of BMP6, IL1RL1, DPP4, CD14 and CAII in epithelial mammary cells, Maria Lucia Katayama, Faculdade de Medicina Universidade de São Paulo, São Paulo, SP Brazil
• Effects of CAPE on growth of cancer stem cells (CSC) derived from triple-negative breast cancer (TNBC) cells, Krystyna Frenkel, NYU School of Medicine, New York, NY, United States
• ErbB/NFκB signaling controls self-renewal of breast cancer stem cells, Noriko Gotoh, Institute of Medical Science, University of Tokyo, Minatoku, Japan
• Essential functions of c-Src in mammary tumor cell proliferation in vivo and in resistance to the ErbB2-targeted inhibitor lapatinib, Harvey Smith, McGill University, Montreal, Quebec, Canada
• Estrogen receptor-α and ras homolog gene family, member A expression in a tamoxifen selected cell line are not controlled by promoter methylation, Kristin Williams, University of Massachusetts - Amherst, Amherst, MA, United States
• Evolutionary pathways in BRCA1-associated human breast tumors, Filipe Martins, Dana-Farber Cancer Institute, Boston, MA, United States
• Fibroblast growth factor receptor 1-induced mammary tumorigenesis requires activation of the epidermal growth factor receptor, Lindsey Bade, University of Minnesota, Minneapolis, MN, United States
• Functional genomic classification of breast cancer using pooled lentivirus shRNA screens, Richard Marcotte, Ontario Cancer Institute, Toronto, Canada
• Genes essential for basal-like breast cancer, Helene McMurray, University of Rochester Medical Center, Rochester, NY, United States
• Genetically modified near normal breast epithelial cell lines., Laura Daley, Sigma-Aldrich, St. Louis, MO, United States
• Glutathione transferase pi expression in breast cancer: An immunohistochemical and molecular study, Debora Zuccari, Faculty of Medicine FAMERP, São José Do Rio Preto, SP Brazil
• GSC promotes tumorigenicity of ERBB2-expressing cells, Kentaro Kumazawa, Waseda University, Tokyo, Japan
• Heterogeneity and selection bias in retroviral transduction: A cautionary tale, Curt Hines, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States
• High expression of SOX9 in estrogen receptor negative breast cancer elucidates a novel mechanism of SOX9 regulation by estrogen receptor alpha, Geetika Chakravarty, TUHSC, Tulane University, New Orleans, LA, United States
• Hyaluronan-based Microenvironmental Probes Profile and Sort Breast Cancer Cellular Heterogeneity, M. Veiseh, Lawrence Berkeley National Laboratories, Berkeley, CA, United States
• Identification and functional characterization of COUP-TFII-nucleolin interaction in breast cancer cells and tumors, Carolyn Klinge, University of Louisville School of Medicine, Louisville, KY, United States
• Identification of a novel oncogene by systematic screening using NMuMG immortalized epithelial cells and a full-length cDNA expression library, Atsuka Matsui, Waseda University, Tokyo, Japan
• Identification of altered genes in tamoxifen resistant breast cancer cells overexpressing Akt, Khyati Shah, University of the Pacific, Stockton, CA, United States
• Identification of blood-based biomarkers for breast cancer detection, Lori Field, Windber Research Institute, Windber, PA, United States
• Identification of PADI2 as a prognostic marker for breast cancer progression and therapeutic target for the treatment of mammary tumors, John McElwee, Cornell University, Ithaca, NY, United States
• Identification of phospho-receptors implicated in the acquisition of resistance to anti-HER2 therapies in breast cancer, Patricia Fernandez, Faculty of Medicine, Barcelona University, Barcelona, Spain
• IL-1β and FGFR1 cooperate to promote mammary tumorigenesis, Thomas Beadnell, University of Minnesota, Minneapolis, MN, United States
• Intra-tumor clonal diversity in therapeutic responses in breast cancer, Vanessa Almendro, Dana-Farber Cancer Institute, Boston, MA, United States
• Investigation of Breast cancer cell death mechanism with irinotecane encapsulated RGD grafted PLGA nanoparticles, Sachin Naik, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat India
• Iodine-supplemented diet prevents the development of resistance in breast cancer chemotherapy. Participation of proliferative peroxisome activated receptor gamma (PPARγ)., Carmen Aceves, Instituto de Neurobiologia, UNAM-Juriquilla, Juriquilla, Queretaro, Mexico
• LPP targeting to focal adhesions in response to TGFβ mediates the migration and invasion of ErbB2-expressing breast cancer cells, Elaine Ngan, McGill University, Montreal, QC Canada
• Mammary glands of F1-F3 generation offspring of rat dams exposed to estradiol during pregnancy exhibit increased expression of DNMT1, DNMT3a and DNMT3b, and methylation of polycomb target genes, Leena Hilakivi-Clarke, Georgetown University, Washington, DC, United States
• Mechanisms of action and biological significance of HER2 mutations in HER2-overexpressing breast cancer, D.R. Boulbes, University of Texas MD Anderson Cancer Center, Houston, TX, United States
• microRNAs expression profiles associated to breast cancer and the triple negative phenotype, Sandra Romero-Cordoba, National Institute of Genomic Medicine, Mexico City, DF Mexico
• miR-200c targets a TrkB/NTF3 autocrine signaling loop to suppress anoikis resistance, Erin Howe, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States
• MiR-545 regulates BRCA1 expression during the cell cycle, Stoil Dimitrov, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
• Monitoring the therapeutic response of breast tumors to targeted pre-operative treatment using high-throughput single nucleus sequencing (SNS), Timour Baslan, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
• Motility induction of breast carcinoma cells by pulmonary laminin 332; implications for lung metastasis, Philip Carpenter, University of California, Irvine, CA, United States
• Mutation of the APC tumor suppressor stimulates breast cancer cell proliferation through hyperactivation of FAK/Src/JNK signaling, Jenifer Prosperi, University of Chicago, Chicago, IL, United States
• Non-coding RNAs and the claudin-low subtype of breast cancer: The long and the short, Jason Herschkowitz, Baylor College of Medicine, Houston, Texas, United States
• Notch receptors have a dual role in breast cancer driving both proliferation of the total tumor population as well as maintaining cancer stem cell self-renewal, Chengzhuo Gao, MedImmune LLC, Gaithersburg, MD, United States
• Novel biomarkers are idenfied using SILAC and MRM technique in human breast cancer cell line and plasma, Hea Young Lee, Cancer Research Institute Seoul National University College of Medicine, Seoul, Korea (Rep.)
• Novel functions of telomerase in breast cancer, Shibani Mukherjee, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
• Novel molecular features associated with sensitivity to the anticancer effects of statins in breast tumor cells, Carolyn Goard, University of Toronto & University Health Network, Toronto, ON, Canada
• Oestrogen receptor sub-type dependent response of breast cancer stem cells to hypoxia is regulated by Notch receptor signalling, Göran Landberg, Breakthrough Breast Cancer Research Unit, Manchester, England
• Overactivation of AKT1 stimulates steroid hormone receptors promoting hormone-independent growth of IBH-6 and IBH-7 human breast cancer cell lines., Marina Riggio, IBYME, Buenos Aires, Argentina
• Overexpression of PKCα in T47D breast cancer cells alters the CD44high/CD24low population, Mary Molloy, University of Illinois at Chicago, Chicago, IL, United States
• Peroxisome proliferator-activated receptor gamma agonist CS7017 reduces preneoplasia and alters mammary cancer subtype induced by BRCA1 loss, Rebecca Nakles, Georgetown University, Washington, DC, United States
• PI3Kinase inhibitor BKM120 is effective tumor treatment in a mouse model of BRCA1-related breast cancer, Gerburg Wulf, BIDMC / HMS, Boston, MA, United States
• PKCα regulates FOXC2 expression in T47D breast cancer cells, Bethany Perez White, University of Illinois at Chicago, Chicago, IL, United States
• Polymorphisms of the EGFR gene and association with histopathological variables in breast cancer, Marcelo Leite, Brazilian National Cancer Institute, Rio De Janeiro, RJ Brazil
• Possible functional role for p63 in the parity-induced mammary stem cell compartment, Alisha Yallowitz, Stony Brook University Medical Center, Stony Brook, NY, United States
• Preclinical Assessment of Medicinal Plant (Vernonia Amygdalyna) in the Treatment of Breast Cancer, Clement Yedjou, Jackson State University, Jackson, MS, United States
• Progesterone receptors enhance breast cancer cell sensitivity to IGF- and estrogen-mediated growth, Andrea Daniel, University of Minnesota, Minneapolis, MN, United States
• RARA promotes the disruption of acinal structures induced by ERBB2 within the three dimensional culture of MCF10A cells, Ayano Doi, Waseda University, Tokyo, Japan
• Re-expression of AMPKα2 inhibits breast cancer growth, Melissa Fox, University of Connecticut Health Center, Farmington, CT, United States
• Regulation of Metastatic Breast Cancer through E2F Transcription Factors, Eran Andrechek, Michigan State University, East Lansing, MI, United States
• Relevance of chromosome 4 in a murine model of breast cancer progression, Victoria Fabris, Instituto de Biología y Medicina Experimental, Capital Federal, Argentina
• Salinomycin as an effective drug in combinatorial treatment of breast carcinoma, Prajakta Oak, Department of Pharmacy, LMU, Munich, Germany
• Schizophyllan decreases the incidence of DMBA–induced mammary tumors in mice through reduction in cell proliferation without inducing apoptosis, Eiman Aleem, Alexandria University, Alexandria, Egypt, Arab Rep.
• Six1 increases tumor initiation capability via regulating multiple signaling pathways, including TGF-β and MEK/ERK signaling, ritsuko iwanaga, University of Colorado Anschutz Medical Center, Aurora, CO, United States
• Splice variant of TRIM37 as a potential molecular marker for breast cancer, Tatiana Ricca, 1International Center of Research and Teaching – CIPE/A.C. Camargo Hospital, São Paulo, Brazil
• Targeting MET and ERBB2 signaling in aggressive breast cancers, Carrie Graveel, Van Andel Research Institute, Grand Rapids, MI, United States
• Targeting Met and Src/Stat3 signaling in a 3-dimensional (3D) matrix invasion model of human basal-like breast cancer, Esther Carefoot, Queen's University, Kingston, ON Canada
• Targeting the RB-pathway to improve treatment of triple negative breast cancer, Erik Knudsen, Thomas Jefferson University, Philadelphia, PA, United States
• Targeting the REST network in triple negative breast cancer, Kristen Meerbrey, Baylor College of Medicine, Houston, TX, United States
• Testing the efficacy of a FAK-specific inhibitor on mammary gland tumorigenesis, Kelly Gillen, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
• The functional relevance of JARID1B in breast cancer, Shoji Yamamoto, Dana-Farber Cancer Institute, Boston, MA, United States
• The HER4 intracellular domain (4ICD) functions as an essential estrogen receptor coactivator mediating estrogen stimulated proliferation of breast tumor cells, Wen Han, Tulane University, New Orleans, LA, United States
• The oncogenic HER2 isoform, HER2Δ16, deregulates microRNA-7 expression to promote breast tumor cell metastatic activity and trastuzumab resistance, Felicia Huynh, Tulane University, New Orleans, LA, United States
• The receptor tyrosine kinase Met synergises with p53 loss to drive mammary tumors that model claudin-low breast cancer, Jennifer Knight, McGill Goodman Cancer Centre, Montreal, QC, Canada
• The role of circulating myeloid cells in breast cancer metastasis to the brain, Lukxmi Balathasan, Gray Institute for Radiation Oncology and Biology, Oxford, England
• The role of H3K4 histone demethylase JARID1B in mouse development, Mike Zou, Yale University, New Haven, CT, United States
• The role of Nek3 kinase in the regulation of paxillin function in breast cancer, Katherine Harrington, Northwestern University, Chicago, IL, United States
• Transcriptional alterations mediated by BRCA1 mutations in triple-negative early age breast tumors, Dirce Carraro, International Center of Research and Teaching, CIPE/Hospital AC Camargo, São Paulo, SP Brazil
• TRANSMODULATION OF ErbB RECEPTORS BY THE PROINFLAMMATORY MEDIATOR SUBSTANCE P, Susana Garcia-Recio, Fundacio Clinic per la Recerca Biomedica, Barcelona, Barcelona Spain
• Uncovering ERα & SRC-1 target genes through a integrative ChIP-seq/expression array approach, Ryan Hartmaier, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
• Use of genomic predictors to identify small molecule sensitizers to chemotherapy, Robin Hallett, McMaster University, Hamilton, Ontario, Canada
• Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries, Marilyn Kwan, Kaiser Permanente Division of Research, Oakland, CA, United States
• Verification of a novel approach to identify disease mechanisms driving resistance to tamoxifen and alternative target pathways for treatment in breast cancer patients, Renee Deehan Kenney, Selventa, Cambridge, MA, United States
• Vitamin D pathway status and the identification of target genes in the mouse mammary gland, Donald Matthews, State University of New York at Albany, Albany, NY, United States